文献速递妇科生殖医学

Mayer-Rokitansky-Küster-Hauser综合征患者泌尿、脱垂及肠道症状的患病率

Prevalence of urinary, prolapse, and bowel symptoms in Mayer-Rokitansky-Küster-Hauser syndrome.
PubMed 文献 · Am J Obstet Gynecol · 2021-02-20

本研究为2019年在线横断面调查,纳入615名MRKH综合征患者,评估其泌尿、脱垂及肠道症状。结果显示70%报告至少一种泌尿症状,脱垂和肠道症状也常见;除近期尿失禁和肛门失禁外,阴道延长治疗与否症状患病率无显著差异。

要点

  • MRKH综合征患者泌尿症状常见(70%),其中79%为此困扰。
  • 阴道延长治疗整体不显著改变盆底症状患病率,但近期尿失禁和肛门失禁除外。
  • 肠管阴道成形术可能与更明显的阴道膨出症状相关。

核心结论

  • 泌尿、脱垂和肠道症状在MRKH综合征患者中常见,应进行评估。
  • 与未行阴道延长治疗相比,阴道延长治疗总体不显著改变盆底症状患病率,但近期尿失禁和肛门失禁除外。
  • 肠管阴道成形术可能与更明显的阴道膨出症状相关。

研究设计与样本

  • 2019年在线横断面调查,由Beautiful You MRKH Foundation通过社交媒体发放。
  • 808名应答者中615名符合纳入标准,来自40个国家,中位年龄29岁(IQR 24-36)。

主要发现

  • 614名中428名(70%)报告至少一种泌尿症状,其中339名(79%)为此困扰。
  • 泌尿症状包括尿失禁210/614(34%)、尿频245/614(40%)、尿急248/614(40%)、排尿疼痛97/614(16%)、反复尿路感染177/614(29%)。
  • 脱垂症状包括下腹压迫感248/612(41%)、骨盆沉重感177/610(29%)、阴道膨出68/609(11%)。
  • 便秘153/611(25%),肛门失禁153/608(25%)。
  • 除近期尿失禁(P=.003)和肛门失禁(P<.001)外,有无阴道延长治疗间盆底症状患病率无显著差异(P>.05)。

临床怎么用

  • 对MRKH综合征患者应常规评估泌尿、脱垂和肠道症状。
  • 阴道延长治疗选择时需考虑对近期尿失禁和肛门失禁的潜在影响。
  • 肠管阴道成形术后应关注阴道膨出症状。

局限性

  • 横断面设计无法确定因果关系。
  • 在线调查可能存在选择偏倚。
  • 81%应答者为白人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Müllerian agenesis, or Mayer-Rokitansky-Küster-Hauser syndrome, occurs in 1 in 4500 to 5000 individuals assigned female sex at birth. Pelvic floor symptoms among individuals with Mayer-Rokitansky-Küster-Hauser syndrome have not been well studied, and it is unknown how vaginal lengthening treatments affect these symptoms. OBJECTIVE: This study aimed to assess urinary, prolapse, and bowel symptoms in individuals with Mayer-Rokitansky-Küster-Hauser syndrome and to determine whether symptoms vary by vaginal lengthening treatment. STUDY DESIGN: We conducted a cross-sectional study in 2019 using an online survey distributed by the Beautiful You MRKH Foundation via social media to individuals with Mayer-Rokitansky-Küster-Hauser syndrome. Demographics, age at and timing of diagnosis, information about vaginal lengthening treatment, urinary symptoms (Michigan Incontinence Symptom Index), prolapse symptoms (Pelvic Organ Prolapse Distress Inventory short-form version), and bowel symptoms (Bristol Stool Form Scale) were obtained. The inclusion criteria included self-reported diagnosis of müllerian agenesis and female sex. Respondents with a history of renal transplant or dialysis, completion of <85% of the survey, and non-English survey responses were excluded. Descriptive analyses were used to describe the sample population. Logistic regression, Kruskal-Wallis, and Fisher exact tests were used to compare the prevalence of pelvic floor symptoms and vaginal lengthening treatments. Associations between age and genitourinary symptoms were investigated with Spearman correlations. RESULTS: Of 808 respondents, 615 met the inclusion criteria, representing 40 countries. 81% of respondents identified as white. The median age of the participants was 29 years (interquartile range, 24-36), with a median age at diagnosis of 16 years (interquartile range, 15-17). Among the 614 respondents, 331 (54%) had vaginal lengthening treatment, 130 of whom (39%) had undergone surgical vaginal lengthening. Of individuals with Mayer-Rokitansky-Küster-Hauser syndrome, 428 of 614 (70%) reported having had one or more urinary symptoms, and 339 of 428 (79%) reported being bothered by these symptoms. Urinary symptoms included urinary incontinence (210 of 614 [34%]), urinary frequency (245 of 614 [40%]), urinary urgency (248 of 614 [40%]), pain with urination (97 of 614 [16%]), and recurrent urinary tract infections (177 of 614 [29%]). Prolapse symptoms included lower abdominal pressure (248 of 612 [41%]), pelvic heaviness or dullness (177 of 610 [29%]), and vaginal bulge (68 of 609 [11%]). In addition, constipation was reported by 153 of 611 respondents (25%), and anal incontinence was reported by 153 of 608 (25%) respondents. Beside recent urinary incontinence (P=.003) and anal incontinence (P<.001), the prevalence of pelvic floor symptoms (P>.05) did not differ significantly between those with and without vaginal lengthening. Among those with surgical vaginal lengthening, symptomatic vaginal bulge was highest in individuals who underwent a bowel vaginoplasty procedure. CONCLUSION: Urinary, prolapse, and bowel symptoms are common among individuals with Mayer-Rokitansky-Küster-Hauser syndrome and should be evaluated in this population. Overall, compared with no vaginal lengthening treatment, having vaginal lengthening treatment is not associated with substantial differences in the prevalence of pelvic floor symptoms, with the exception of recent urinary incontinence and anal incontinence. Our data suggested that bowel vaginoplasty may be associated with greater symptoms of vaginal bulge. More robust studies are needed to determine the impact of various vaginal lengthening treatments on pelvic floor symptoms.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pennesi CM, English EM, Bell S, et al. Prevalence of urinary, prolapse, and bowel symptoms in Mayer-Rokitansky-Küster-Hauser syndrome. Am J Obstet Gynecol. 2021. PMID: 33621544. doi:10.1016/j.ajog.2021.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。